U035 Merkel Cell Carcinoma: Diagnosis, Management, and Controversies
DESCRIPTION
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma with a higher disease-specific mortality than melanoma. MCC is rare, but the incidence is increasing in the US. Clinical management is challenging due to the lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and encouraged by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. This session will focus on current concepts in diagnosis and management of all stages of disease and recurrence.
LEARNING OBJECTIVES
Utilize recent developments in clinical management of Merkel cell carcinoma to guide multidisciplinary care of patients with all stages of MCC.
Identify areas of consensus and controversy regarding the clinical management of MCC.
Detect and diagnose disease recurrence. Understand the utility of measuring circulating tumor DNA in monitoring for disease recurrence.
SCHEDULE
7:30 AM
Diagnosis and Management
Kelly L Harms, PhD, MD, FAAD
7:55 AM
Surveillance including utilization of circulating tumor DNA
Lisa Zaba, MD, PhD, FAAD
8:20 AM
Questions and Answers
DIRECTOR
Kelly L Harms, PhD, MD, FAAD
SPEAKER
Lisa Zaba, MD, PhD, FAAD
DISCLOSURES
Kelly L Harms, PhD, MD, FAAD
No financial relationships exist with ineligible companies.
Lisa Zaba, MD, PhD, FAAD
No financial relationships exist with ineligible companies.